Highlights
Bone is a common metastatic site in renal cell carcinoma (RCC).
HGF/c-Met pathway is particularly relevant in tumors with bone metastases.
c-Met/HGF pathway is involved in RCC progression, conferring poor prognosis.
Several c-Met targeting therapies are currently in clinical development.
c-Met expression is an important therapeutic target in RCC with bone metastases.
Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.
Stratifying by stage the residual tumour (OR=2.4; p=0.0001) , age (OR=1.9 P=0.0001), and the performance status (OR=1.2; p=0.03) resulted as independent survival prognostic factors according to Cox multivariate analysis. Conclusion* Our data suggest that patients aged !70 can tolerate radical surgical treatments in the same way as younger patients without a significant increase in morbidity and, obviously, without ignoring the appropriate geriatric precautions. Furthermore, maximal surgical effort with optimal cytoreduction should be considered the gold standard regardless of age.Therefore, our data underlines the importance of managing these patients within Gynecologic Oncology units equipped with a multidisciplinary team.
Background: The benefit of adjuvant chemotherapy (AdjCT) in all stage II patients (pts) with colon cancer is not clear. Characterization of high-risk subgroups may shed light on this matter. The aim of this study was to determine patterns of AdjCT prescription and its impact on disease-free survival (DFS) in stage II CC.Methods: Unicentric retrospective cohort of pts with stage II colon adenocarcinoma identified on the Portuguese national oncologic database between 2007 and 2018. Pts were categorized into two groups: not receiving and receiving AdjCT; AdjCT was characterized as capecitabine monotherapy (Cap) vs oxaliplatin-based (Oxali). abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S139
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.